Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

Human Vaccines

Volumn 6, Issue 11, 2010, Pages 931-935

  Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer disease; Immunotherapy; Neurodegeneration; Tau oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ANTIBODY; TAU PROTEIN; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DISEASE COURSE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; MEMORY DISORDER; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; REVIEW; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; IMMUNIZATION, PASSIVE; TAU PROTEINS;

EID: 78649360496     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.11.12689     Document Type: Review

References (81)

1. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24:1121-59.
2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82:239-59.
3. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008; 18:484-96.
4. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991; 1:213-6.
5. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 1996; 165:3-12.
6. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 1998; 95:13103-7. (Pubitemid 128621114)
7. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splicesite mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702-5.
8. Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative disorders. Hum Mol Genet 2006; 15:188-95.
9. Delacourte A, Buee L. Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol 2000; 13:371-6.
10. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999; 58:188-97. (Pubitemid 29088942)
11. Bretteville A, Planel E. Tau aggregates: toxic, inert or protective species? J Alzheimers Dis 2008; 14:431-6.
12. Congdon EE, Duff KE. Is tau aggregation toxic or protective? J Alzheimers Dis 2008; 14:453-7.
13. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42:631-9.
14. Bird TD, Nochlin D, Poorkaj P, Cherrier M, Kaye J, Payami H, et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 1999; 122:741-56.
15. Hernandez F, Avila J. Tau aggregates and tau pathology. J Alzheimers Dis 2008; 14:449-52.
16. Rankin CA, Gamblin TC. Assessing the toxicity of tau aggregation. J Alzheimers Dis 2008; 14:411-6.
17. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003; 162:1623-7.
18. Tabaton M, Cammarata S, Manetto V, Perry G, Mancardi G. Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neurosci Lett 1989; 103:259-62. (Pubitemid 19214398)
19. Castellani RJ, Nunomura A, Lee HG, Perry G, Smith MA. Phosphorylated tau: toxic, protective or none of the above. J Alzheimers Dis 2008; 14:377-83.
20. Gotz J, Ittner LM, Fandrich M, Schonrock N. Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? J Alzheimers Dis 2008; 14:423-9.
21. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41:17-24. (Pubitemid 27057088)
22. Terry RD. Do neuronal inclusions kill the cell? J Neural Transm Suppl 2000; 59:91-3.
23. van de Nes JA, Nafe R, Schlote W. Non-tau based neuronal degeneration in Alzheimer's disease - an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res 2008; 1213:152-65.
24. Vogt BA, Vogt LJ, Vrana KE, Gioia L, Meadows RS, Challa VR, et al. Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp Neurol 1998; 153:8-22.
25. Brunden KR, Trojanowski JQ, Lee VM. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis 2008; 14:393-9.
26. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 2009; 284:4230-7.
27. Marx J. Alzheimer's disease. A new take on tau. Science 2007; 316:1416-7.
28. Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R. Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 2009.
29. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280:17294-300.
30. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett 2006; 580:4842-50. (Pubitemid 44286844)
31. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras- Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 2008; 37:673-81.
32. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005; 25:5446-54.
33. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009; 29:10741-9.
34. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53:337-51.
35. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 2008; 28:737-48. (Pubitemid 351159036)
36. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001; 293:711-4.
37. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH. Human wildtype tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002; 34:509-19.
38. Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, et al. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 2009; 119:1382-95.
39. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007; 27:3650-62. (Pubitemid 46557687)
40. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006; 168:1598-607.
41. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 2007; 46:3856-61.
42. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 2006; 54:197-201.
43. Yamazaki M, Hasegawa M, Mori O, Murayama S, Tsuchiya K, Ikeda K, Cet al. Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2005; 64:839-46. (Pubitemid 41434666)
44. Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 2009; 21:359-63.
45. Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008; 5:443-57.
46. Iqbal K, Grundke-Iqbal I. Tau phosphatase activity as a therapeutic target for AD. Drug News Perspect 1998; 11:10-4.
47. Gong CX, Iqbal K. Hyperphosphorylation of microtubule- associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 2008; 15:2321-8.
48. Johnson GV, Jope RS, Binder LI. Proteolysis of tau by calpain. Biochem Biophys Res Commun 1989; 163:1505-11.
49. Sengupta S, Horowitz PM, Karsten SL, Jackson GR, Geschwind DH, Fu Y, et al. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 2006; 45:15111-9. (Pubitemid 44937024)
50. Trojanowski JQ, Smith AB, Huryn D, Lee VM. Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Expert Opin Pharmacother 2005; 6:683-6.
51. Zhang B, Maiti A, Shively S, Lakhani F, McDonald- Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005; 102:227-31.
52. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 2009; 48:1740-52.
53. Deiana S, Harrington CR, Wischik CM, Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2009; 202:53-65.
54. Duff K, Kuret J, Congdon EE. Disaggregation of Tau as a Therapeutic Approach to Tauopathies. Curr Alzheimer Res.
55. Wisniewski T, Boutajangout A. Vaccination as a Therapeutic Approach to Alzheimer's Disease. Mt Sinai J Med 77:17-31.
56. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372:216-23. (Pubitemid 351978111)
57. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006; 65:1040-8.
58. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9:448-52.
59. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27:9115-29. (Pubitemid 47312068)
60. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25:402-5.
61. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006; 63:1459-67.
62. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002; 103:26-35. (Pubitemid 36075309)
63. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. Domains of tau protein, differential phosphorylation and dynamic instability of microtubules. Mol Biol Cell 1995; 6:1887-902.
64. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-9.
65. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283:29639-43.
66. Glabe CG. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci 2004; 29:542-7.
67. Gotz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9:532-44.
68. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008; 131:3299-310.
69. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298:1379.
70. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25:629-36.
71. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006; 6:404-16.
72. Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 2008; 15:555-69.
73. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1:24. (Pubitemid 40617823)
74. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, et al. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated microhemorrhages in aged Tg2576 mice. Proc Natl Acad Sci USA 2009; 106:4501-6.
75. Chauhan NB. Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 2007; 85:451-63.
76. Kitazawa M, Vasilevko V, Cribbs DH, LaFerla FM. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci 2009; 29:6132-41.
77. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006; 281:1599-604. (Pubitemid 43752475)
78. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45:675-88.
79. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46:857-68.
80. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007; 282:18895-906. (Pubitemid 47100144)
81. Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009; 29:13589-602.